Latest Amrep Corp (AXR) Headlines NYSE stocks p
Post# of 17
Posted On: 03/14/2014 11:33:51 AM
Latest Amrep Corp (AXR) Headlines
NYSE stocks posting largest volume decreases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
Spirit AeroSystems to Release Fourth Quarter and Full-Year 2013 Financial Results on February 6
PR Newswire - Thu Jan 23, 6:30AM CST
Spirit AeroSystems Holdings, Inc. (NYSE: SPR) will release its fourth quarter and full-year 2013 financial results at 6:30 a.m. Central time on Thursday, February 6, 2014.
Starpharma Commences Dendrimer-Docetaxel Clinical Trial
Business Wire - Wed Jan 22, 10:49PM CST
Starpharma (ASX:SPL)(OTCQX:SPHRY) today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere(R)) chemotherapeutic product, referred to as DEP(TM)-Docetaxel.
Shares of AXR Down 17.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 20, 9:11AM CST
SmarTrend identified a Downtrend for Amrep (NYSE:AXR) on October 2nd, 2013 at $8.29. In approximately 3 months, Amrep has returned 17.20% as of today's recent price of $6.86.
AMREP Reports Second Quarter Fiscal 2014 Results
PR Newswire - Mon Dec 16, 3:23PM CST
AMREP Corporation (NYSE: AXR) today reported net income of $52,000, or $0.01 per share, for its fiscal 2014 second quarter ended October 31, 2013, compared to net income of $276,000, or $0.05 per share, for the second quarter of the prior fiscal year. For the first six months of 2014, the Company had a net loss of $635,000, or $0.09 per share, compared to a net loss of $332,000, or $0.06 per share, for the same period of 2013. Results for the second quarter of fiscal 2014 included an adjustment reducing a reserve for doubtful accounts receivable from a magazine wholesaler by $300,000 ($189,000 after tax, or $0.03 per share). The results for the first six months of 2013 included a pre-tax, non-cash impairment charge of $169,000 ($107,000 after tax, or $0.02 per share) reflecting the write-down of a real estate investment asset during the first quarter of 2013. Revenues were $22,763,000 and $43,272,000 for the second quarter and first six months of 2014 compared to $21,317,000 and $40,913,000 for the same periods last year.
Amrep Has Returned 17.7% Since SmarTrend Recommendation (AXR)
Comtex SmarTrend(R) - Mon Dec 09, 10:02AM CST
SmarTrend identified a Downtrend for Amrep (NYSE:AXR) on October 2nd, 2013 at $8.29. In approximately 2 months, Amrep has returned 17.68% as of today's recent price of $6.82.
NYSE stocks posting largest percentage decreases
AP - Thu Dec 05, 5:11PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
NYSE stocks posting largest volume decreases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
Spirit AeroSystems to Release Fourth Quarter and Full-Year 2013 Financial Results on February 6
PR Newswire - Thu Jan 23, 6:30AM CST
Spirit AeroSystems Holdings, Inc. (NYSE: SPR) will release its fourth quarter and full-year 2013 financial results at 6:30 a.m. Central time on Thursday, February 6, 2014.
Starpharma Commences Dendrimer-Docetaxel Clinical Trial
Business Wire - Wed Jan 22, 10:49PM CST
Starpharma (ASX:SPL)(OTCQX:SPHRY) today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere(R)) chemotherapeutic product, referred to as DEP(TM)-Docetaxel.
Shares of AXR Down 17.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 20, 9:11AM CST
SmarTrend identified a Downtrend for Amrep (NYSE:AXR) on October 2nd, 2013 at $8.29. In approximately 3 months, Amrep has returned 17.20% as of today's recent price of $6.86.
AMREP Reports Second Quarter Fiscal 2014 Results
PR Newswire - Mon Dec 16, 3:23PM CST
AMREP Corporation (NYSE: AXR) today reported net income of $52,000, or $0.01 per share, for its fiscal 2014 second quarter ended October 31, 2013, compared to net income of $276,000, or $0.05 per share, for the second quarter of the prior fiscal year. For the first six months of 2014, the Company had a net loss of $635,000, or $0.09 per share, compared to a net loss of $332,000, or $0.06 per share, for the same period of 2013. Results for the second quarter of fiscal 2014 included an adjustment reducing a reserve for doubtful accounts receivable from a magazine wholesaler by $300,000 ($189,000 after tax, or $0.03 per share). The results for the first six months of 2013 included a pre-tax, non-cash impairment charge of $169,000 ($107,000 after tax, or $0.02 per share) reflecting the write-down of a real estate investment asset during the first quarter of 2013. Revenues were $22,763,000 and $43,272,000 for the second quarter and first six months of 2014 compared to $21,317,000 and $40,913,000 for the same periods last year.
Amrep Has Returned 17.7% Since SmarTrend Recommendation (AXR)
Comtex SmarTrend(R) - Mon Dec 09, 10:02AM CST
SmarTrend identified a Downtrend for Amrep (NYSE:AXR) on October 2nd, 2013 at $8.29. In approximately 2 months, Amrep has returned 17.68% as of today's recent price of $6.82.
NYSE stocks posting largest percentage decreases
AP - Thu Dec 05, 5:11PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
(0)
(0)